Literature DB >> 14727840

Kinetics of pramlintide degradation in aqueous solution as a function of temperature and pH.

R A Kenley1, S Tracht, A Stepanenko, M Townsend, J L'Italien.   

Abstract

The stability of the 37-amino acid peptide pramlintide, in aqueous solution, was studied as a function of pH and temperature. Samples of pramlintide formulated as a parenteral product were exposed to elevated temperatures and to realistic storage conditions for as long as 30 months. Pramlintide degradation was monitored by three high-performance liquid chromatography (HPLC) methods: a reversed-phase (RP-HPLC) and a strong-cation exchange (SCX-HPLC) method for percentage purity determination by area normalization, plus a second RP-HPLC method for potency determination versus external standards. The pH-rate profile for pramlintide shows increasing degradation rate constants with increasing pH over the range pH = 3.5 to 5.0. The Arrhenius expression for pramlintide degradation at pH = 4.0 over the temperature range 5 degrees C to 50 degrees C is ln(k(0))= 37.39-21.900/RT, where k(0) is the zero-order rate constant (in %/mo) for pramlintide degradation. The pramlintide parenteral product formulated at pH = 4.0 is extremely stable, with percentage purity and percentage potency loss of only approximately 2% over 30 months at 5 degrees C. The formulated pramlintide drug product has acceptable shelf life for long-term storage at 5 degrees C and up to a 30-day patient use when stored at ambient temperature.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 14727840      PMCID: PMC2784819          DOI: 10.1208/pt010207

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  12 in total

1.  Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes.

Authors:  R G Thompson; A Gottlieb; K Organ; J Koda; J Kisicki; O G Kolterman
Journal:  Diabet Med       Date:  1997-07       Impact factor: 4.359

2.  Isolation and identification of peptide degradation products of heat stressed pramlintide injection drug product.

Authors:  C Hekman; W DeMond; T Dixit; S Mauch; M Nuechterlein; A Stepanenko; J D Williams; M Ye
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

3.  Amylin's pramlintide best of bad bunch of diabetes drugs.

Authors:  V Brower
Journal:  Nat Biotechnol       Date:  1997-10       Impact factor: 54.908

4.  Rates of nonenzymatic deamidation of glutaminyl and asparaginyl residues in pentapeptides.

Authors:  A B Robinson; J W Scotchler; J H McKerrow
Journal:  J Am Chem Soc       Date:  1973-11-28       Impact factor: 15.419

5.  Amylin and diabetes.

Authors:  S Amiel
Journal:  Lancet       Date:  1993-05-15       Impact factor: 79.321

6.  Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial.

Authors:  R G Thompson; J Peterson; A Gottlieb; J Mullane
Journal:  Diabetes       Date:  1997-04       Impact factor: 9.461

Review 7.  The role of amylin in the physiology of glycemic control.

Authors:  W A Scherbaum
Journal:  Exp Clin Endocrinol Diabetes       Date:  1998       Impact factor: 2.949

8.  Orthogonal HPLC methods for quantitating related substances and degradation products of pramlintide.

Authors:  W Demond; R A Kenley; J L Italien; D Lokensgard; G Weilersbacher; K Herman
Journal:  AAPS PharmSciTech       Date:  2000-03-24       Impact factor: 3.246

9.  Deamidation via cyclic imide of asparaginyl peptides: dependence on salts, buffers and organic solvents.

Authors:  S Capasso; L Mazzarella; A Zagari
Journal:  Pept Res       Date:  1991 Jul-Aug

Review 10.  Amylin regulation of carbohydrate metabolism.

Authors:  A Young; R Pittner; B Gedulin; W Vine; T Rink
Journal:  Biochem Soc Trans       Date:  1995-05       Impact factor: 5.407

View more
  1 in total

1.  Pramlintide injection drug product robustness studies.

Authors:  R A Kenley; F Bancroft; J L'Italien; A Stepanenko; M Townsend; T Dixit
Journal:  AAPS PharmSciTech       Date:  2000-03-18       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.